常染色体显性多囊肾病管理的最新进展
本文综述了常染色体显性多囊肾病(ADPKD)在诊断、预后评估和发病机制方面的进展,强调总肾脏体积是良好的预后标志物,可对患者进行疾病进展分层。文章提出早期肾内科转诊和肾脏保护策略可能产生显著效果,并讨论了血管加压素V2受体拮抗剂等疾病修饰治疗的应用。
要点
- 总肾脏体积可用于ADPKD预后分层,区分缓慢或快速进展疾病。
- 所有ADPKD患者均应优化肾脏保护措施,包括严格血压控制和生活方式调整。
- 血管加压素V2受体拮抗剂是可能改变疾病进程的治疗,已在多国获批。
核心结论
- ADPKD是最常见的单基因导致ESKD的病因,目前没有哪种肾脏疾病比ADPKD更适合采用肾脏保护策略。
- 早期肾内科转诊和实施肾脏保护策略可能对ADPKD患者产生显著效果。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- ADPKD的特征是肾脏囊肿持续发展、高血压和肾实质破坏。
- 总肾脏体积是良好的预后标志物,可将患者分层为缓慢或快速进展疾病,影响管理决策。
- 血管加压素V2受体拮抗剂已在多个国家获批,最近获美国FDA批准;生长抑素类似物等其他新药正在临床试验中。
关键数值与推荐
- 部分患者仅需监测和基础优化肾脏保护措施,如严格血压控制和生活方式及饮食改变。
- 其他患者可从疾病修饰治疗中获益,如血管加压素V2受体拮抗剂。
临床怎么用
- 应早期转诊肾内科并实施肾脏保护策略。
- 使用总肾脏体积进行疾病分层和预后评估,以指导管理。
- 根据疾病进展风险,选择监测和基础保护措施或疾病修饰治疗。
局限性
- 本文为观点性综述,未报告系统检索方法或证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic cause of ESKD, is characterized by relentless development of kidney cysts, hypertension, and destruction of the kidney parenchyma. Over the past few years, major advancements in diagnosing, prognosticating, and understanding the pathogenesis and natural course of the disease have been made. Currently, no kidney disease is more suitable for nephron-protective strategies. Early nephrology referral and implementation of these strategies may have a substantial effect. Total kidney volume is a good prognostication marker and allows stratification of patients into slow or rapid progressing disease, with implications for their management. Measurement of total kidney volume, disease stratification, and prognostication are possible using readily available tools. Although some patients require only monitoring and basic optimized kidney protective measures, such as rigorous BP control and various lifestyle and dietary changes, others will benefit from disease-modifying treatments. Vasopressin V2 receptor antagonists, a likely disease-modifying treatment, has been approved in several countries and recently by the US Food and Drug Administration; other therapies, such as somatostatin analogs and other novel agents, are currently in clinical trials. The purpose of this article is to present our views on the optimal management to delay kidney disease progression in ADPKD.
引用
- Chebib FT, Torres VE. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 30049849. doi:10.2215/CJN.03960318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。